The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities

被引:51
|
作者
Conti, Rena M. [1 ,2 ]
Bach, Peter B. [3 ]
机构
[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, New York, NY 10021 USA
关键词
PHYSICIAN RELATIONS; COST; INTEGRATION;
D O I
10.1377/hlthaff.2014.0540
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The federal 340B program gives participating hospitals and other medical providers deep discounts on outpatient drugs. Named for a section of the Veterans Health Care Act of 1992, the program's original intent was to help low-income and uninsured patients. But the program has come under scrutiny by critics who contend that some hospitals exploit the drug discounts to generate profits instead of either investing in programs for the poor or passing the discounts along to patients and insurers. We examined whether the program is expanding in ways that could maximize hospitals' ability to generate profits from the 340B drug discounts. We matched data for 960 hospitals and 3,964 affiliated clinics registered with the 340B program in 2012 with the socioeconomic characteristics of their communities from the US Census Bureau's American Community Survey. We found that hospital-affiliated clinics that registered for the 340B program in 2004 or later served communities that were wealthier and had higher rates of health insurance compared to communities served by hospitals and clinics that registered for the program before 2004. Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics.
引用
收藏
页码:1786 / 1792
页数:7
相关论文
共 50 条
  • [21] Public Hospitals May Use the 340B Program Differently Than Nonprofit Hospitals
    McGlave, Claire
    Nikpay, Sayeh
    JAMA HEALTH FORUM, 2024, 5 (05): : e240846
  • [22] Implementation of a $4 generic drug program in a 340B pharmacy
    Bright, David R.
    Adams, Alex J.
    Akala, Folasade O.
    Lengel, Aaron J.
    Martin, Steven J.
    Powers, Mary F.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (11) : 929 - 931
  • [23] The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B
    Han, Dan
    JOURNAL OF HEALTH ECONOMICS, 2023, 89
  • [24] Outcomes of the 340B Drug Pricing Program A Scoping Review
    Knox, Ryan P.
    Wang, Junyi
    Feldman, William B.
    Kesselheim, Aaron S.
    Sarpatwari, Ameet
    JAMA HEALTH FORUM, 2023, 4 (11): : E233716
  • [25] REASON FOR CONCERN: GROWTH AND CHANGE IN COMMUNITIES SERVED BY THE 340B PROGRAM
    Rowan, K.
    VALUE IN HEALTH, 2017, 20 (05) : A25 - A25
  • [26] The 340B Drug Discount Program Preserved After US Supreme Court Review-But Chevron Remains Vulnerable
    Curfman, Gregory
    Cole, Justin
    JAMA HEALTH FORUM, 2022, 3 (09):
  • [27] US Supreme Court Review of the 340B Drug Discount Program-American Hospital Association v Becerra
    Cole, Justin
    Gardiner, Jason
    Curfman, Gregory
    JAMA HEALTH FORUM, 2022, 3 (03):
  • [28] 340B Drug Pricing Program and Hospital Provision of Uncompensated Care
    Desai, Sunita M.
    McWilliams, J. Michael
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (10): : 432 - +
  • [29] Expanding rural-area oncology service access through 340B Drug Pricing Program participation
    Nierengarten, Mary Beth
    CANCER, 2023, 129 (22) : 3517 - 3517
  • [30] The 340B Discount Program: Outpatient Prescription Dispensing Patterns Through Contract Pharmacies In 2012
    Clark, Bobby L.
    Hou, John
    Chou, Chia-Hung
    Huang, Elbert S.
    Conti, Rena
    HEALTH AFFAIRS, 2014, 33 (11) : 2012 - 2017